Sarepta Therapeutics Inc (SRPT)

Net profit margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	235,239	-535,977	-703,488	-418,780	-554,128
Revenue	US$ in thousands	1,901,980	1,243,340	933,013	701,887	540,099
Net profit margin		12.37%	-43.11%	-75.40%	-59.66%	-102.60%

December 31, 2024 calculation

Net profit margin = Net income ÷ Revenue
= $235,239K ÷ $1,901,980K
= 12.37%

The net profit margin is an important financial metric that indicates the percentage of revenue that translates into profit after all expenses have been deducted.

Analyzing the net profit margin of Sarepta Therapeutics Inc over the past five years reveals a fluctuating trend. In December 31, 2020, the company incurred a net profit margin of -102.60%, indicating that the expenses surpassed the revenue significantly, resulting in a substantial loss.

However, there was an improvement in the net profit margin in the following years. By December 31, 2021, the net profit margin improved to -59.66%, indicating that the company managed to reduce its losses compared to the previous year.

Subsequently, by December 31, 2022, the net profit margin further decreased to -75.40%, suggesting that the company's expenses still exceeded its revenue but at a reduced rate compared to the previous year.

The trend continued to show improvement in December 31, 2023, with a net profit margin of -43.11%, signifying that the company was moving towards profitability as expenses decreased relative to revenue.

Finally, in December 31, 2024, Sarepta Therapeutics Inc achieved a positive net profit margin of 12.37%, indicating that the company was able to generate profit after deducting all expenses from its revenue.

Overall, the analysis of the net profit margin demonstrates a fluctuating trend for Sarepta Therapeutics Inc over the past five years, with the company moving from significant losses to profitability by the end of the period. It highlights the company's efforts to control expenses and improve operational efficiency to enhance its financial performance.